DEF: Schrodinger Sets June 22, 2026 Annual Meeting

Schrodinger, Inc. announced its 2026 Annual Meeting of Stockholders, scheduled for June 22, 2026, to vote on director elections, executive compensation, and equity plan amendments.

Summary

• Schrodinger, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on Monday, June 22, 2026, at 12:00 p.m. Eastern time.
• Key proposals include the election of three Class III directors, an advisory vote on executive compensation, an amendment to the 2022 Equity Incentive Plan to increase the share pool by 3,000,000 shares, and ratification of KPMG LLP as the independent registered public accounting firm for fiscal year 2026.
• The record date for stockholders entitled to vote is April 23, 2026.
• Proxy materials will be distributed via the internet, with a Notice of Internet Availability of Proxy Materials to be mailed around April 28, 2026.
• The company's board of directors recommends voting FOR all proposals.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting standard corporate governance procedures and a proactive approach to talent management through equity incentives, while acknowledging the potential dilution and the presence of underwater stock options.

Positives

• The company is holding its annual meeting, indicating ongoing corporate governance practices.
• The proposed amendment to the equity incentive plan aims to attract, retain, and motivate key employees, which is crucial for growth.
• The company continues to engage with institutional investors on executive compensation and corporate governance matters.
• The board of directors is recommending approval of all proposals, suggesting confidence in the company's direction and management.

Negatives

• The filing indicates that a significant portion of outstanding stock options (11,101,981 options) are underwater as of April 1, 2026, meaning their exercise prices exceed the current trading price of the company's common stock.
• The proposed increase in shares for the equity incentive plan would increase the company's overhang to 29.10% from 25.07%.

Risks

• The company's ability to attract, retain, and motivate key employees is dependent on its stock-based compensation programs, and failure to approve the equity incentive plan amendment could have an adverse impact.
• The company faces competition for talent in a highly competitive labor market.
• The company's success depends on its ability to further develop its computational platform and the demand for its software.
• Risks associated with drug development and commercialization, including clinical trial uncertainties and regulatory reviews, are ongoing.

Future Outlook

The company plans to continue granting equity awards under the amended plan for approximately two to three years, depending on participation, market practices, and stock price. The company also continues to advance its drug discovery programs and predictive toxicology initiative.

Management Comments

• We believe that hosting a virtual meeting will enable greater stockholder attendance and participation from any location around the world.
• Our board of directors believes that our success depends, in large part, on our ability to maintain a competitive position by attracting, retaining and motivating key employees with experience and ability.
• We believe that our stock-based compensation programs have been integral to our success in the past and will be important to our ability to succeed in the future.
• We believe that maintaining a classified board structure is reflective of peer and industry practice for relatively new public companies within five to ten years of initial public offering in order to maintain stability of the board during the early years following the initial public offering.

Industry Context

StockSavvy.ai notes that Schrodinger's proposal to increase its equity incentive plan shares is a common strategy for growth-stage technology and biotech companies aiming to attract and retain talent in a competitive market. The company's focus on drug discovery and computational platforms aligns with broader industry trends towards AI and data-driven R&D.

Comparison to Industry Standards

• The company's peer group for compensation benchmarking includes companies like 10x Genomics, Adaptive Biotechnologies, Recursion Pharmaceuticals, and Certara, which are comparable in the life sciences and software sectors.
• The proposed increase in equity awards aims to keep Schrodinger competitive with industry standards for attracting and retaining talent.
• The company's classified board structure is noted as being reflective of peer and industry practice for companies in their early years as public entities.

Corporate Governance

Related Party Transactions

• Consulting agreement with Richard Friesner, a co-founder and director, for molecular modeling software development, with payments totaling $436,800 in 2025 and additional fees in 2026.
• Royalty payments to Columbia University for licensed software, a portion of which is distributed to Dr. Richard Friesner and his laboratory.
• Agreement with Gates Ventures, LLC for a research project on battery materials, with extended consideration of up to $6,000,000.
• Richard A. Friesner has pledged 334,113 shares of common stock as collateral for a loan.

Stakeholder Impact

• Shareholders will vote on key proposals impacting equity dilution and executive compensation.
• Employees may benefit from the proposed increase in equity awards, which is intended to attract, retain, and motivate talent.
• The company's commitment to corporate sustainability is highlighted, potentially impacting stakeholders interested in ESG factors.

Next Steps

• Stockholders are to vote on the proposed matters at the Annual Meeting.
• The company will file a Current Report on Form 8-K with preliminary and final voting results.
• If approved, the company intends to register the additional shares of common stock reserved for issuance under the Amended Plan by filing a Registration Statement on Form S-8.

Key Dates

Recommendation

The filing details routine annual meeting proposals, including an equity incentive plan increase and director elections. While the company is focused on growth and talent retention, the presence of underwater stock options and the potential for increased dilution warrant a cautious 'hold' stance until further performance improvements are evident.

Keywords

Schrodinger, Annual Meeting, Proxy Statement, Director Election, Executive Compensation, Equity Incentive Plan, KPMG LLP, Virtual Meeting, Stockholder Vote